|
JP5600063B2
(ja)
|
2007-10-19 |
2014-10-01 |
セルジーン アビロミクス リサーチ， インコーポレイテッド |
ヘテロアリール化合物およびその使用
|
|
US7989465B2
(en)
*
|
2007-10-19 |
2011-08-02 |
Avila Therapeutics, Inc. |
4,6-disubstituted pyrimidines useful as kinase inhibitors
|
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
|
JP2011523646A
(ja)
|
2008-05-21 |
2011-08-18 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
キナーゼ阻害剤としてのリン誘導体
|
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
AU2009262068C1
(en)
*
|
2008-06-27 |
2015-07-02 |
Celgene Car Llc |
Heteroaryl compounds and uses thereof
|
|
KR101705158B1
(ko)
|
2009-05-05 |
2017-02-09 |
다나-파버 캔서 인스티튜트 인크. |
Ｅｇｆｒ 억제제 및 질환 치료방법
|
|
WO2010129802A1
(en)
*
|
2009-05-06 |
2010-11-11 |
Portola Pharmaceuticals, Inc. |
Inhibitors of jak
|
|
CN102458402B
(zh)
|
2009-06-12 |
2013-10-02 |
百时美施贵宝公司 |
用作激酶调节剂的烟酰胺化合物
|
|
CN102713618B
(zh)
|
2009-09-16 |
2015-07-15 |
新基阿维罗米克斯研究公司 |
蛋白激酶复合物和抑制剂
|
|
US8466155B2
(en)
*
|
2009-10-02 |
2013-06-18 |
Boehringer Ingelheim International Gmbh |
Pyrimidines
|
|
WO2011082285A1
(en)
|
2009-12-30 |
2011-07-07 |
Avila Therapeutics, Inc. |
Ligand-directed covalent modification of protein
|
|
EP2571361A4
(en)
|
2010-05-19 |
2013-11-13 |
Univ North Carolina |
PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
|
|
BR112012029647A2
(pt)
|
2010-05-21 |
2016-08-02 |
Chemilia Ab |
novos derivados de pirimidinas
|
|
AU2011260323A1
(en)
|
2010-06-04 |
2012-11-15 |
F. Hoffmann-La Roche Ag |
Aminopyrimidine derivatives as LRRK2 modulators
|
|
PH12013500246A1
(en)
|
2010-08-10 |
2019-10-11 |
Celgene Avilomics Res Inc |
Besylate salt of a btk inhibitor
|
|
JP5956999B2
(ja)
|
2010-11-01 |
2016-07-27 |
セルジーン アヴィロミクス リサーチ， インコーポレイテッド |
ヘテロアリール化合物およびその使用
|
|
BR112013010564B1
(pt)
|
2010-11-01 |
2021-09-21 |
Celgene Car Llc |
Compostos heterocíclicos e composições compreendendo os mesmos
|
|
KR101566091B1
(ko)
|
2010-11-10 |
2015-11-04 |
에프. 호프만-라 로슈 아게 |
Lrrk2 조절제로서 피라졸 아미노피리미딘 유도체
|
|
EP2637502B1
(en)
|
2010-11-10 |
2018-01-10 |
Celgene CAR LLC |
Mutant-selective egfr inhibitors and uses thereof
|
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
|
MX2013010898A
(es)
|
2011-03-24 |
2013-12-06 |
Chemilia Ab |
Novedoso derivados de la pirimidina.
|
|
EP2694486B1
(en)
|
2011-04-01 |
2018-01-10 |
University of Utah Research Foundation |
Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
|
|
EP3628665B1
(en)
|
2011-04-01 |
2022-11-02 |
University of Utah Research Foundation |
Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase
|
|
TWI548621B
(zh)
|
2011-04-22 |
2016-09-11 |
標誌製藥公司 |
經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法
|
|
JP5902293B2
(ja)
|
2011-04-25 |
2016-04-13 |
アッシャー・サード・イニシアティブ・インコーポレイテッド |
ピラゾロピリダジンおよび網膜変性疾患およびアッシャー症候群に伴う聴覚損失を治療するための方法
|
|
AU2012250517B2
(en)
|
2011-05-04 |
2016-05-19 |
Takeda Pharmaceutical Company Limited |
Compounds for inhibiting cell proliferation in EGFR-driven cancers
|
|
DK3686193T3
(da)
|
2011-07-27 |
2022-05-30 |
Astrazeneca Ab |
2-(2,4,5-substitueret anilino)pyrimidinforbindelser
|
|
BR112014007788A2
(pt)
|
2011-10-03 |
2017-04-18 |
Univ North Carolina Chapel Hill |
compostos de pirrolopirimidina para tratamento do câncer
|
|
JP2014532658A
(ja)
*
|
2011-10-28 |
2014-12-08 |
セルジーン アヴィロミクス リサーチ， インコーポレイテッド |
ブルトン型チロシンキナーゼ疾患または障害を治療する方法
|
|
US9586965B2
(en)
|
2012-01-13 |
2017-03-07 |
Acea Biosciences Inc. |
Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
|
|
CA2861010A1
(en)
|
2012-01-13 |
2013-07-18 |
Xiao Xu |
Heterocyclic compounds and uses as anticancer agents
|
|
US9464089B2
(en)
|
2012-01-13 |
2016-10-11 |
Acea Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
US9034885B2
(en)
|
2012-01-13 |
2015-05-19 |
Acea Biosciences Inc. |
EGFR modulators and uses thereof
|
|
HUE033177T2
(en)
|
2012-01-17 |
2017-11-28 |
Astellas Pharma Inc |
Pyrazine carboxamide compound
|
|
JP6317320B2
(ja)
|
2012-03-15 |
2018-04-25 |
セルジーン シーエーアール エルエルシー |
上皮成長因子受容体キナーゼ阻害剤の塩
|
|
ES2880109T3
(es)
|
2012-03-15 |
2021-11-23 |
Celgene Car Llc |
Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico
|
|
JP6469567B2
(ja)
*
|
2012-05-05 |
2019-02-13 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
|
|
WO2013173518A1
(en)
*
|
2012-05-16 |
2013-11-21 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
|
JP2015517574A
(ja)
*
|
2012-05-22 |
2015-06-22 |
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル |
がん治療のためのピリミジン化合物
|
|
CA2876689C
(en)
|
2012-06-13 |
2022-04-26 |
Incyte Corporation |
Substituted tricyclic compounds as fgfr inhibitors
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
WO2014039452A1
(en)
*
|
2012-09-04 |
2014-03-13 |
Celgene Avilomics Research, Inc. |
Methods of treating a bruton's tyrosine kinase disease or disorder
|
|
JP6313772B2
(ja)
|
2012-10-04 |
2018-04-18 |
ユニヴァーシティー オブ ユタ リサーチ ファウンデーション |
チロシン受容体キナーゼｂｔｋ阻害剤である置換ｎ−（３−（ピリミジン−４−イル）フェニル）アクリルアミド類似体
|
|
KR102194611B1
(ko)
*
|
2012-10-04 |
2020-12-23 |
유니버시티 오브 유타 리서치 파운데이션 |
티로신 수용체 키나아제 btk 억제제로서 치환된 n-(3-(피리미딘-4-일)페닐)아크릴아미드 유사체
|
|
WO2014062774A1
(en)
|
2012-10-17 |
2014-04-24 |
The University Of North Carolina At Chapel Hill |
Pyrazolopyrimidine compounds for the treatment of cancer
|
|
US9227976B2
(en)
|
2012-10-25 |
2016-01-05 |
Usher Iii Initiative, Inc. |
Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
|
|
US8765762B2
(en)
|
2012-10-25 |
2014-07-01 |
Usher III, Initiative, Inc. |
Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome
|
|
WO2014081712A2
(en)
*
|
2012-11-20 |
2014-05-30 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with bruton's tyrosine kinase
|
|
US20140142129A1
(en)
*
|
2012-11-20 |
2014-05-22 |
Celgene Avilomics Research, Inc, |
Methods of treating a disease or disorder associated with bruton's tyrosine kinase
|
|
TW201427666A
(zh)
*
|
2012-11-20 |
2014-07-16 |
Celgene Avilomics Res Inc |
治療和布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶相關之疾病或失調的方法
|
|
US20140142128A1
(en)
*
|
2012-11-20 |
2014-05-22 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with bruton's tyrosine kinase
|
|
WO2014085225A1
(en)
*
|
2012-11-27 |
2014-06-05 |
The University Of North Carolina At Chapel Hill |
Pyrimidine compounds for the treatment of cancer
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
US9126950B2
(en)
*
|
2012-12-21 |
2015-09-08 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
HK1218249A1
(zh)
|
2013-01-25 |
2017-02-10 |
Rigel Pharmaceuticals, Inc. |
用於治疗炎症性肠道疾病的化合物和方法
|
|
CN105188371A
(zh)
|
2013-02-08 |
2015-12-23 |
西建阿维拉米斯研究公司 |
Erk抑制剂及其用途
|
|
US20140357636A1
(en)
*
|
2013-02-21 |
2014-12-04 |
Wayne Rothbaum |
Treatment of Skeletal-Related Disorders
|
|
EP2961746B1
(en)
|
2013-02-28 |
2018-01-03 |
Bristol-Myers Squibb Company |
Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
|
|
AR094929A1
(es)
|
2013-02-28 |
2015-09-09 |
Bristol Myers Squibb Co |
Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
|
|
PT2970205T
(pt)
|
2013-03-14 |
2019-08-26 |
Tolero Pharmaceuticals Inc |
Inibidores da jak2 e da alk2 e métodos para a sua utilização
|
|
EP2970190A1
(en)
|
2013-03-14 |
2016-01-20 |
Respivert Limited |
Kinase inhibitors
|
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
|
PH12015502383B1
(en)
|
2013-04-19 |
2023-02-03 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
PL2989106T3
(pl)
|
2013-04-25 |
2017-08-31 |
Beigene, Ltd. |
Połączone związki heterocykliczne jako inhibitory kinazy białkowej
|
|
EP2994456A4
(en)
*
|
2013-05-06 |
2017-01-04 |
Clovis Oncology, Inc. |
Salts of an epidermal growth factor receptor kinase inhibitor
|
|
GB201309085D0
(en)
|
2013-05-20 |
2013-07-03 |
Redx Pharma Ltd |
Compounds
|
|
EP3483167A1
(en)
|
2013-06-26 |
2019-05-15 |
AbbVie Inc. |
Primary carboxamides as btk inhibitors
|
|
BR112016000195A8
(pt)
*
|
2013-07-11 |
2019-12-31 |
Acea Biosciences Inc |
compostos heterocíclicos, composição farmacêutica, combinação, seu uso, e método para inibir uma atividade da tirosina quinase btk ou jak, egfr, alk, pdgfr, blk, bmx/etk, flt3(d835y), itk, tec, txk, e suas respectivas vias
|
|
JP6510510B2
(ja)
*
|
2013-07-11 |
2019-05-08 |
ベータ ファーマシューティカルズ カンパニー リミテッド |
プロテインチロシンキナーゼモジュレーター及び使用方法
|
|
MX360498B
(es)
|
2013-08-12 |
2018-11-05 |
Taiho Pharmaceutical Co Ltd |
Compuesto novedoso de pirimidina fusionada o sal del mismo.
|
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
|
SMT202300039T1
(it)
|
2013-09-13 |
2023-03-17 |
Beigene Switzerland Gmbh |
Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
|
|
WO2015039613A1
(zh)
*
|
2013-09-18 |
2015-03-26 |
北京韩美药品有限公司 |
抑制btk和/或jak3激酶活性的化合物
|
|
US10329270B2
(en)
|
2013-10-21 |
2019-06-25 |
Merck Patent Gmbh |
Heteroaryl compounds as BTK inhibitors and uses thereof
|
|
CA3103411A1
(en)
|
2013-10-25 |
2015-04-30 |
Pharmacyclics Llc |
Use of ibrutinib for treating and preventing chronic graft versus host disease
|
|
US9415049B2
(en)
*
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
NZ715903A
(en)
|
2014-01-30 |
2017-06-30 |
Signal Pharm Llc |
Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
|
|
US11039621B2
(en)
|
2014-02-19 |
2021-06-22 |
Corning Incorporated |
Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
|
|
US9622483B2
(en)
|
2014-02-19 |
2017-04-18 |
Corning Incorporated |
Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
|
|
US11039620B2
(en)
|
2014-02-19 |
2021-06-22 |
Corning Incorporated |
Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
|
|
CN104860941B
(zh)
*
|
2014-02-25 |
2017-03-22 |
上海海雁医药科技有限公司 |
2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
|
|
US9340540B2
(en)
|
2014-02-28 |
2016-05-17 |
Nimbus Lakshmi, Inc. |
TYK2 inhibitors and uses thereof
|
|
US20170173011A1
(en)
*
|
2014-03-07 |
2017-06-22 |
Celgene Avilomics Research, Inc. |
Methods of treating a bruton's tyrosine kinase disease or disorder
|
|
US9649309B2
(en)
|
2014-04-11 |
2017-05-16 |
The University Of North Carolina At Chapel Hill |
Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity
|
|
US9879008B2
(en)
|
2014-04-14 |
2018-01-30 |
Shanghai Haiyan Pharmaceutical Technology Co., Ltd. |
2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, preparation method therefor and medicinal use thereof
|
|
EP3131550B1
(en)
*
|
2014-04-16 |
2021-05-26 |
Signal Pharmaceuticals, LLC |
Methods for treating cancer using tor kinase inhibitor combination therapy with a histone deacetylase inhibitor
|
|
CN106536503B
(zh)
*
|
2014-04-18 |
2019-09-06 |
北京澳合药物研究院有限公司 |
一种酪氨酸激酶抑制剂及其用途
|
|
CN104130265B
(zh)
*
|
2014-04-29 |
2017-01-25 |
苏州景泓生物技术有限公司 |
一种含有螺环或桥环的嘧啶类化合物
|
|
GB201410430D0
(en)
|
2014-06-11 |
2014-07-23 |
Redx Pharma Ltd |
Compounds
|
|
TWI726608B
(zh)
|
2014-07-03 |
2021-05-01 |
英屬開曼群島商百濟神州有限公司 |
抗pd-l1抗體及其作為治療及診斷之用途
|
|
CN105315285B
(zh)
*
|
2014-07-25 |
2017-12-08 |
上海海雁医药科技有限公司 |
2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途
|
|
MY195016A
(en)
|
2014-08-04 |
2023-01-03 |
Nuevolution As |
Optionally Fused Heterocyclyl-Substituted Derivatives of Pyrimidine Useful for The Treatment of Inflammatory, Metabolic, Oncologic and Autoimmune Diseases
|
|
CN117164657A
(zh)
|
2014-08-12 |
2023-12-05 |
莫纳什大学 |
定向淋巴的前药
|
|
WO2016025561A1
(en)
|
2014-08-13 |
2016-02-18 |
Celgene Avilomics Research, Inc. |
Forms and compositions of an erk inhibitor
|
|
ES2914099T3
(es)
*
|
2014-08-25 |
2022-06-07 |
Salk Inst For Biological Studi |
Inhibidores novedosos de ULK1 y métodos de uso de los mismos
|
|
CN105399686B
(zh)
*
|
2014-09-16 |
2018-05-22 |
深圳微芯生物科技有限责任公司 |
嘧啶衍生物、其制备方法及其应用
|
|
CN105481778B
(zh)
*
|
2014-09-16 |
2019-06-04 |
深圳微芯生物科技股份有限公司 |
嘧啶衍生物、其制备方法及其应用
|
|
CN105399685B
(zh)
*
|
2014-09-16 |
2018-05-22 |
深圳微芯生物科技有限责任公司 |
作为选择性jak3和/或jak1激酶抑制剂的芳杂环化合物的制备方法及其应用
|
|
RS62017B1
(sr)
|
2014-09-17 |
2021-07-30 |
Celgene Car Llc |
Mk2 inhibitori i njihova upotreba
|
|
EP3205650B1
(en)
*
|
2014-10-11 |
2021-08-04 |
Shanghai Hansoh Biomedical Co., Ltd. |
Egfr inhibitor, and preparation and application thereof
|
|
US10059689B2
(en)
|
2014-10-14 |
2018-08-28 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
NZ731185A
(en)
|
2014-10-29 |
2024-03-22 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for mt1-mmp
|
|
CN105601573B
(zh)
|
2014-11-24 |
2021-07-02 |
中国科学院上海药物研究所 |
2-氨基嘧啶类化合物及其药物组合物和应用
|
|
JP2017537327A
(ja)
*
|
2014-12-11 |
2017-12-14 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
Ｂｔｋ阻害剤のアッセイ
|
|
US9513297B2
(en)
|
2014-12-16 |
2016-12-06 |
Signal Pharmaceuticals, Llc |
Methods for measurement of inhibition of c-Jun N-terminal kinase in skin
|
|
EP3712134B1
(en)
|
2014-12-16 |
2023-11-29 |
Signal Pharmaceuticals, LLC |
Salts of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
|
|
EP3250557B1
(en)
|
2015-01-29 |
2024-11-20 |
Signal Pharmaceuticals, LLC |
Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
|
|
TWI605049B
(zh)
|
2015-01-30 |
2017-11-11 |
Taiho Pharmaceutical Co Ltd |
Novel salts of condensed pyrimidine compounds and their crystallization
|
|
DK3120852T3
(da)
*
|
2015-01-30 |
2019-07-29 |
Taiho Pharmaceutical Co Ltd |
Præventivt og/eller terapeutisk middel til immunsygdomme
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
CA2976790C
(en)
|
2015-02-20 |
2024-02-27 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2016138352A1
(en)
|
2015-02-27 |
2016-09-01 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
JP6853234B2
(ja)
*
|
2015-07-09 |
2021-03-31 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
Ｂｔｋ阻害剤としてのピリミジン誘導体及びその使用
|
|
EP3325432B1
(en)
|
2015-07-24 |
2020-09-02 |
Celgene Corporation |
Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
|
|
CA2996177A1
(en)
|
2015-08-31 |
2017-03-09 |
Pharmacyclics Llc |
Btk inhibitor combinations for treating multiple myeloma
|
|
EP4327809A3
(en)
|
2015-09-02 |
2024-04-17 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors and uses thereof
|
|
CN118063537A
(zh)
|
2015-09-08 |
2024-05-24 |
莫纳什大学 |
定向淋巴的前药
|
|
US10683308B2
(en)
|
2015-09-11 |
2020-06-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
|
US10611766B2
(en)
|
2015-09-16 |
2020-04-07 |
Loxo Oncology Inc. |
Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
|
|
CN106554347B
(zh)
*
|
2015-09-25 |
2020-10-30 |
浙江博生医药有限公司 |
Egfr激酶抑制剂及其制备方法和应用
|
|
EP3359159B1
(en)
|
2015-10-09 |
2023-06-07 |
ACEA Therapeutics, Inc. |
Pharmaceutical compositions of a pyrrolopyrimidine kinase inhibitor, and methods of making same
|
|
WO2017068412A1
(en)
*
|
2015-10-21 |
2017-04-27 |
Otsuka Pharmaceutical Co., Ltd. |
Benzolactam compounds as protein kinase inhibitors
|
|
MX389001B
(es)
|
2015-10-23 |
2025-03-20 |
Navitor Pharm Inc |
Moduladores de interacción de sestrina-gator2 y sus usos.
|
|
WO2017106352A1
(en)
|
2015-12-14 |
2017-06-22 |
Raze Therapeutics, Inc. |
Caffeine inhibitors of mthfd2 and uses thereof
|
|
CN114605327B
(zh)
|
2015-12-16 |
2025-03-11 |
洛克索肿瘤学股份有限公司 |
可用作激酶抑制剂的化合物
|
|
CN107021963A
(zh)
|
2016-01-29 |
2017-08-08 |
北京诺诚健华医药科技有限公司 |
吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
|
|
PT3426243T
(pt)
|
2016-03-09 |
2021-08-19 |
Raze Therapeutics Inc |
Inibidores de 3-fosfoglicerato desidrogenase e utilizações dos mesmos
|
|
EP4234552A3
(en)
|
2016-03-09 |
2023-10-18 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
|
US10709708B2
(en)
|
2016-03-17 |
2020-07-14 |
The University Of North Carolina At Chapel Hill |
Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
|
|
US11337969B2
(en)
|
2016-04-08 |
2022-05-24 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
|
CN105968056A
(zh)
*
|
2016-05-28 |
2016-09-28 |
大连医科大学 |
二芳基嘧啶类化合物，组合物及用途
|
|
US10988465B2
(en)
|
2016-06-21 |
2021-04-27 |
X4 Pharmaceuticals, Inc. |
CXCR4 inhibitors and uses thereof
|
|
JP6994767B2
(ja)
|
2016-06-21 |
2022-01-14 |
エックス４ ファーマシューティカルズ， インコーポレイテッド |
Ｃｘｃｒ４阻害剤およびその使用
|
|
EP3808748B1
(en)
|
2016-06-21 |
2026-05-20 |
X4 Pharmaceuticals, Inc. |
Substituted piperidines as cxcr4-inhibitors
|
|
KR20230047507A
(ko)
|
2016-06-27 |
2023-04-07 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
암 치료 조합
|
|
WO2018007885A1
(en)
|
2016-07-05 |
2018-01-11 |
Beigene, Ltd. |
COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
|
|
IL293319B1
(en)
|
2016-08-16 |
2026-01-01 |
Beone Medicines Ltd |
Crystal structure of s)–7–(1–acryloylpiperidin–4–yl)–2–(4–)phenoxyphenyl)–4,5,6,7–tetra–hydropyrazolo(1,5–a)pyrimidine–3–carboxamide, methods of preparation and uses thereof
|
|
CN110087680B
(zh)
|
2016-08-19 |
2024-03-19 |
百济神州有限公司 |
使用包含btk抑制剂的组合产品治疗癌症
|
|
CN106316886A
(zh)
*
|
2016-08-24 |
2017-01-11 |
泰州精英化成医药科技有限公司 |
顺式‑3‑（叔丁氧羰基氨基）环己烷甲酸的制备方法
|
|
CN109982687A
(zh)
|
2016-09-19 |
2019-07-05 |
梅制药公司 |
联合疗法
|
|
TWI763722B
(zh)
|
2016-10-14 |
2022-05-11 |
美商林伯士拉克許米公司 |
Tyk2抑制劑及其用途
|
|
CN110300590A
(zh)
|
2016-10-21 |
2019-10-01 |
林伯士拉克许米公司 |
Tyk2抑制剂及其用途
|
|
CN107973754B
(zh)
*
|
2016-10-25 |
2020-04-14 |
清华大学 |
一种小分子抑制剂及其制备方法与其在多发性骨髓瘤治疗中的应用
|
|
JP2020023441A
(ja)
*
|
2016-11-02 |
2020-02-13 |
国立大学法人九州大学 |
Ｅｇｆｒ阻害及び腫瘍治療に有用な新規化合物
|
|
CA3042049A1
(en)
|
2016-11-03 |
2018-05-11 |
Juno Therapeutics, Inc. |
Combination therapy of a t cell therapy and a btk inhibitor
|
|
EP3538091A4
(en)
|
2016-11-08 |
2020-06-10 |
Navitor Pharmaceuticals, Inc. |
PHENYL AMINO PIPERIDINE MTORC INHIBITORS AND USES THEREOF
|
|
US20180193270A1
(en)
|
2016-11-29 |
2018-07-12 |
PureTech Health LLC |
Exosomes for delivery of therapeutic agents
|
|
US11091451B2
(en)
|
2016-12-05 |
2021-08-17 |
Raze Therapeutics, Inc. |
SHMT inhibitors and uses thereof
|
|
EP3559018A1
(en)
|
2016-12-23 |
2019-10-30 |
Bicyclerd Limited |
Peptide derivatives having novel linkage structures
|
|
CN106632273A
(zh)
*
|
2016-12-29 |
2017-05-10 |
大连医科大学 |
含唑杂环的嘧啶类化合物，组合物及其用途
|
|
ES2985986T3
(es)
|
2017-01-06 |
2024-11-08 |
Bicyclerd Ltd |
Conjugado biciclo para tratar el cáncer
|
|
CN108329274B
(zh)
*
|
2017-01-13 |
2021-09-03 |
正大天晴药业集团股份有限公司 |
布鲁顿酪氨酸激酶抑制剂
|
|
EP3573989A4
(en)
|
2017-01-25 |
2020-11-18 |
Beigene, Ltd. |
CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES
|
|
CN108498477A
(zh)
*
|
2017-02-27 |
2018-09-07 |
江苏奥赛康药业股份有限公司 |
一种2-氨基嘧啶类化合物的药用组合物及其制备方法
|
|
AU2018230737B2
(en)
|
2017-03-08 |
2022-09-22 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors, uses, and methods for production thereof
|
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
|
AU2017408099A1
(en)
|
2017-04-07 |
2019-11-07 |
ACEA Therapeutics, Inc. |
Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
|
|
RS65386B1
(sr)
|
2017-04-14 |
2024-04-30 |
Biogen Ma Inc |
Benzoazepinski analozi kao sredstva za inhibiciju brutonove tirozin kinaze
|
|
GB201706327D0
(en)
|
2017-04-20 |
2017-06-07 |
Otsuka Pharma Co Ltd |
A pharmaceutical compound
|
|
EP3615550A1
(en)
|
2017-04-27 |
2020-03-04 |
BicycleTx Limited |
Bicyclic peptide ligands and uses thereof
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
IL271491B2
(en)
|
2017-06-22 |
2023-09-01 |
Celgene Corp |
Treatment of carcinoma of the liver characterized by hepatitis b virus infection
|
|
WO2019002842A1
(en)
|
2017-06-26 |
2019-01-03 |
Bicyclerd Limited |
BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
|
|
EP3645569A4
(en)
|
2017-06-26 |
2021-03-24 |
BeiGene, Ltd. |
IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
|
|
IL317854A
(en)
|
2017-07-28 |
2025-02-01 |
Takeda Pharmaceuticals Co |
TYK2 inhibitors and their uses
|
|
JP7670481B2
(ja)
|
2017-08-04 |
2025-04-30 |
バイスクルテクス・リミテッド |
Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
|
|
WO2019034009A1
(en)
|
2017-08-12 |
2019-02-21 |
Beigene, Ltd. |
BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY
|
|
WO2019034866A1
(en)
|
2017-08-14 |
2019-02-21 |
Bicyclerd Limited |
BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
|
|
WO2019034868A1
(en)
|
2017-08-14 |
2019-02-21 |
Bicyclerd Limited |
CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
|
|
EP3670500A4
(en)
*
|
2017-08-18 |
2020-12-16 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
CHEMICAL COMPOUND, PHARMACEUTICAL COMPOSITION OF IT, CORRESPONDING USE AND APPLICATION
|
|
EP4306524A3
(en)
|
2017-08-29 |
2024-09-11 |
PureTech LYT, Inc. |
Lymphatic system-directing lipid prodrugs
|
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
|
KR102383561B1
(ko)
*
|
2017-09-07 |
2022-04-06 |
한국화학연구원 |
테트라히드로이소퀴놀린기로 치환된 피리미딘 유도체 화합물, 이의 광학이성질체, 또는 이의 약학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 조성물
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
MX2020003190A
(es)
|
2017-09-22 |
2020-11-11 |
Kymera Therapeutics Inc |
Degradadores de proteinas y usos de los mismos.
|
|
WO2019090198A1
(en)
|
2017-11-06 |
2019-05-09 |
Bristol-Myers Squibb Company |
Isofuranone compounds useful as hpk1 inhibitors
|
|
WO2019099311A1
(en)
|
2017-11-19 |
2019-05-23 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
|
US11786529B2
(en)
|
2017-11-29 |
2023-10-17 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
|
|
GB201721265D0
(en)
|
2017-12-19 |
2018-01-31 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for EphA2
|
|
EP3727362A4
(en)
|
2017-12-19 |
2021-10-06 |
PureTech LYT, Inc. |
MYCOPHENOLIC ACID LIPID PRODRUGS AND THEIR USES
|
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
|
TWI825046B
(zh)
|
2017-12-19 |
2023-12-11 |
英商拜西可泰克斯有限公司 |
Epha2特用之雙環胜肽配位基
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
|
|
CA3089762A1
(en)
|
2018-01-29 |
2019-08-01 |
Merck Patent Gmbh |
Gcn2 inhibitors and uses thereof
|
|
AU2019212969B2
(en)
|
2018-01-29 |
2025-01-23 |
Merck Patent Gmbh |
GCN2 inhibitors and uses thereof
|
|
TWI798334B
(zh)
|
2018-01-31 |
2023-04-11 |
大陸商迪哲（江蘇）醫藥股份有限公司 |
Ｅｒｂｂ／ｂｔｋ抑制劑
|
|
CA3091775A1
(en)
|
2018-02-23 |
2019-08-29 |
Bicycletx Limited |
Multimeric bicyclic peptide ligands
|
|
KR20260028873A
(ko)
|
2018-02-27 |
2026-03-04 |
아텍스 바이오파마 인코포레이티드 |
Tcr-nck 상호 작용의 억제제로서의 크로멘 유도체
|
|
BR112020020246A8
(pt)
|
2018-04-05 |
2022-10-18 |
Sumitomo Dainippon Pharma Oncology Inc |
Inibidores de cinase axl e uso dos mesmos
|
|
EP3784669B1
(en)
|
2018-04-24 |
2023-10-25 |
Vertex Pharmaceuticals Incorporated |
Pteridinone compounds and uses thereof
|
|
IL301501B2
(en)
|
2018-04-24 |
2024-10-01 |
Vertex Pharma |
Antiproliferation compounds and uses thereof
|
|
CN118286225A
(zh)
|
2018-04-26 |
2024-07-05 |
辉瑞公司 |
作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物
|
|
BR112020022185A2
(pt)
|
2018-05-03 |
2021-02-02 |
Juno Therapeutics Inc |
terapia de combinação de uma terapia de células t do receptor de antígeno quimérico (car) e um inibidor de quinase
|
|
KR102956194B1
(ko)
|
2018-05-04 |
2026-04-23 |
인사이트 코포레이션 |
Fgfr 억제제의 염
|
|
RS66310B1
(sr)
|
2018-05-04 |
2025-01-31 |
Incyte Corp |
Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
|
|
US10980784B2
(en)
|
2018-06-15 |
2021-04-20 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
|
GB201810316D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
US12454520B2
(en)
|
2018-07-06 |
2025-10-28 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
KR20210038906A
(ko)
|
2018-07-26 |
2021-04-08 |
스미토모 다이니폰 파마 온콜로지, 인크. |
비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
|
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
|
EP3846793B1
(en)
|
2018-09-07 |
2024-01-24 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
|
JP7619951B2
(ja)
|
2018-10-15 |
2025-01-22 |
武田薬品工業株式会社 |
Ｔｙｋ２阻害剤およびその使用
|
|
WO2020084305A1
(en)
|
2018-10-23 |
2020-04-30 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
|
CN109608444B
(zh)
*
|
2018-11-27 |
2022-02-11 |
中国药科大学 |
含异吲哚啉酮的erk抑制剂及其制备方法与用途
|
|
AU2019389174A1
(en)
|
2018-11-30 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2020112937A1
(en)
|
2018-11-30 |
2020-06-04 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
GB201820295D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for MT1-MMP
|
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
|
WO2020128527A1
(en)
|
2018-12-21 |
2020-06-25 |
Bicyclerd Limited |
Bicyclic peptide ligands specific for pd-l1
|
|
EP3897849A1
(en)
|
2018-12-21 |
2021-10-27 |
BicycleTx Limited |
Bicyclic peptide ligands specific for pd-l1
|
|
CA3126034A1
(en)
|
2019-01-23 |
2020-07-30 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
CN109776495A
(zh)
*
|
2019-01-31 |
2019-05-21 |
李佳睿 |
抗肿瘤化合物及其制备方法与用途
|
|
WO2020165600A1
(en)
|
2019-02-14 |
2020-08-20 |
Bicycletx Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
|
WO2020168197A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
|
|
TW202100520A
(zh)
|
2019-03-05 |
2021-01-01 |
美商英塞特公司 |
作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
JP2022526159A
(ja)
|
2019-03-29 |
2022-05-23 |
アストラゼネカ・アクチエボラーグ |
非小細胞肺がんの治療に使用するためのオシメルチニブ
|
|
US11919904B2
(en)
|
2019-03-29 |
2024-03-05 |
Incyte Corporation |
Sulfonylamide compounds as CDK2 inhibitors
|
|
US20220184222A1
(en)
|
2019-04-02 |
2022-06-16 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
|
KR102980990B1
(ko)
|
2019-04-05 |
2026-06-25 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Stat 분해제 및 이의 용도
|
|
WO2020223558A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
Tricyclic amine compounds as cdk2 inhibitors
|
|
WO2020223469A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
|
|
HRP20231310T1
(hr)
|
2019-05-10 |
2024-02-02 |
Deciphera Pharmaceuticals, Llc |
Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene
|
|
HUE065486T2
(hu)
|
2019-05-10 |
2024-05-28 |
Deciphera Pharmaceuticals Llc |
Fenilaminopirimidinamid autophágia inhibitorok és azok felhasználási eljárásai
|
|
US11458149B1
(en)
|
2019-05-31 |
2022-10-04 |
Ikena Oncology, Inc. |
TEAD inhibitors and uses thereof
|
|
US12624044B2
(en)
|
2019-06-10 |
2026-05-12 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
WO2020251972A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
EP3981399A4
(en)
|
2019-06-10 |
2023-05-31 |
BeiGene Switzerland GmbH |
ORAL SOLID TABLET WITH A TYROSINE KINAS INHIBITOR AND METHOD OF MANUFACTURE THEREOF
|
|
ES3072710T3
(en)
|
2019-06-17 |
2026-07-03 |
Deciphera Pharmaceuticals Llc |
Aminopyrimidine amide autophagy inhibitors and methods of use thereof
|
|
WO2020257495A1
(en)
*
|
2019-06-18 |
2020-12-24 |
Purdue Research Foundation |
Inhibitors of erythrocyte band 3 tyrosine phosphorylation and uses thereof
|
|
PH12022500002A1
(en)
|
2019-06-28 |
2023-04-03 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US12558427B2
(en)
|
2019-07-17 |
2026-02-24 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
CN110305140B
(zh)
*
|
2019-07-30 |
2020-08-04 |
上海勋和医药科技有限公司 |
二氢吡咯并嘧啶类选择性jak2抑制剂
|
|
TWI860386B
(zh)
|
2019-07-30 |
2024-11-01 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
|
WO2021030537A1
(en)
|
2019-08-14 |
2021-02-18 |
Incyte Corporation |
Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
|
CA3150492A1
(en)
|
2019-09-11 |
2021-03-18 |
Donna L. Romero |
Usp30 inhibitors and uses thereof
|
|
US12215105B2
(en)
|
2019-09-13 |
2025-02-04 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
|
CN112574207B
(zh)
*
|
2019-09-30 |
2023-04-11 |
南京药石科技股份有限公司 |
Erk1/2蛋白激酶抑制剂及其用途
|
|
US12122767B2
(en)
|
2019-10-01 |
2024-10-22 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
CR20220170A
(es)
|
2019-10-11 |
2022-10-10 |
Incyte Corp |
Aminas bicíclicas como inhibidoras de la cdk2
|
|
GEP20247679B
(en)
|
2019-10-14 |
2024-10-10 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
JP2023500352A
(ja)
*
|
2019-11-08 |
2023-01-05 |
深▲セン▼微芯生物科技股▲フン▼有限公司 |
移植片対宿主病を予防又は治療するための化合物
|
|
CA3162886A1
(en)
*
|
2019-11-26 |
2021-06-03 |
Shenzhen Chipscreen Biosciences Co., Ltd. |
Composition containing aromatic heterocyclic compound in amorphous form, and preparation method therefor and use thereof
|
|
WO2021113479A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
MX2022006691A
(es)
|
2019-12-04 |
2022-09-19 |
Incyte Corp |
Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
|
|
EP4069223A4
(en)
|
2019-12-05 |
2023-12-20 |
Janssen Pharmaceutica NV |
RAPAMYCIN ANALOGS AND THEIR USES
|
|
WO2021119159A1
(en)
|
2019-12-10 |
2021-06-17 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
|
CA3161878A1
(en)
|
2019-12-17 |
2021-06-24 |
Matthew M. Weiss |
Irak degraders and uses thereof
|
|
AU2020405446A1
(en)
|
2019-12-20 |
2022-05-26 |
Nuevolution A/S |
Compounds active towards nuclear receptors
|
|
BR112022012205A2
(pt)
|
2019-12-20 |
2022-09-13 |
Nuevolution As |
Compostos ativos para receptores nucleares
|
|
WO2021133917A1
(en)
|
2019-12-23 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Smarca inhibitors and uses thereof
|
|
US11679109B2
(en)
|
2019-12-23 |
2023-06-20 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
WO2021138391A1
(en)
|
2019-12-30 |
2021-07-08 |
Tyra Biosciences, Inc. |
Indazole compounds
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
CN111620852B
(zh)
*
|
2020-01-19 |
2023-05-09 |
镇江植生源农业科技有限公司 |
一种5-氯-嘧啶-2,4-二胺类化合物及其制备方法和应用
|
|
JP7810970B2
(ja)
|
2020-02-05 |
2026-02-04 |
シーポート・セラピューティクス・インコーポレイテッド |
神経ステロイドの脂質プロドラッグ
|
|
US12594277B2
(en)
|
2020-02-14 |
2026-04-07 |
Salk Institute For Biological Studies |
Macrocyclic ULK1/2 inhibitors
|
|
AR121506A1
(es)
|
2020-03-03 |
2022-06-08 |
Pic Therapeutics Inc |
Inhibidores del eif4e y sus usos
|
|
WO2021188948A1
(en)
|
2020-03-19 |
2021-09-23 |
Kymera Therapeutics, Inc. |
Mdm2 degraders and uses thereof
|
|
JP7713954B2
(ja)
|
2020-03-31 |
2025-07-28 |
ヌエヴォリューション・アクティーゼルスカブ |
核内受容体に対して活性な化合物
|
|
CA3174252A1
(en)
|
2020-03-31 |
2021-10-07 |
Nuevolution A/S |
Compounds active towards nuclear receptors
|
|
KR20230051425A
(ko)
|
2020-04-07 |
2023-04-18 |
미토브리지, 인크. |
Cd38 억제제
|
|
EP4161521A4
(en)
|
2020-06-03 |
2024-07-10 |
Kymera Therapeutics, Inc. |
DEUTERED IRAQ DEGRADERS AND USES THEREOF
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
CN111646978B
(zh)
*
|
2020-06-11 |
2021-12-21 |
浙江大学 |
N2-取代烷氧芳环-2-氨基嘧啶类衍生物及应用
|
|
WO2022006518A1
(en)
*
|
2020-07-02 |
2022-01-06 |
The Cleveland Clinic Foundation |
Compounds and methods of promoting oligodendrocyte precursor differentiation
|
|
EP4178580B1
(en)
|
2020-07-09 |
2025-11-05 |
Usher III Initiative, Inc. |
Bf 844 for use in the treatment of cancer
|
|
CN116348476A
(zh)
|
2020-08-03 |
2023-06-27 |
拜斯科技术开发有限公司 |
基于肽的接头
|
|
WO2022038158A1
(en)
|
2020-08-17 |
2022-02-24 |
Bicycletx Limited |
Bicycle conjugates specific for nectin-4 and uses thereof
|
|
US20260167619A2
(en)
*
|
2020-09-22 |
2026-06-18 |
Beone Medicines I Gmbh |
Indoline compounds and derivatives as egfr inhibitors
|
|
WO2022072632A1
(en)
*
|
2020-09-30 |
2022-04-07 |
Scorpion Therapeutics, Inc. |
Bicyclic compounds for use in the treatment cancer
|
|
EP4232425A4
(en)
|
2020-10-23 |
2024-07-24 |
Nimbus Clotho, Inc. |
Ctps1 inhibitors and uses thereof
|
|
EP4255895A1
(en)
|
2020-12-02 |
2023-10-11 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
US12606568B2
(en)
|
2020-12-09 |
2026-04-21 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
AR124547A1
(es)
|
2020-12-30 |
2023-04-05 |
Kymera Therapeutics Inc |
Degradadores de irak y sus usos
|
|
JP2024506858A
(ja)
*
|
2021-02-02 |
2024-02-15 |
リミナル・バイオサイエンシーズ・リミテッド |
Ｇｐｒ８４アンタゴニストおよびその使用
|
|
KR20230153387A
(ko)
|
2021-02-02 |
2023-11-06 |
리미널 바이오사이언시스 리미티드 |
Gpr84 길항제 및 이의 용도
|
|
WO2022174253A1
(en)
|
2021-02-12 |
2022-08-18 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
MX2023009178A
(es)
|
2021-02-15 |
2023-08-21 |
Kymera Therapeutics Inc |
Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
|
|
WO2022174268A1
(en)
|
2021-02-15 |
2022-08-18 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
CN117295737A
(zh)
|
2021-03-05 |
2023-12-26 |
林伯士萨顿公司 |
Hpk1拮抗剂和其用途
|
|
WO2022213062A1
(en)
|
2021-03-29 |
2022-10-06 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
CN115160319B
(zh)
*
|
2021-04-01 |
2023-12-26 |
西安新通药物研究股份有限公司 |
含1,3-苯并二氧戊环结构的化合物及其制备方法与用途
|
|
US20240216330A1
(en)
|
2021-04-02 |
2024-07-04 |
Biogen Ma Inc. |
Combination treatment methods of multiple sclerosis
|
|
US12325697B2
(en)
|
2021-04-09 |
2025-06-10 |
Nimbus Clio, Inc. |
CBL-B modulators and uses thereof
|
|
EP4323405A1
(en)
|
2021-04-12 |
2024-02-21 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
AU2022258968A1
(en)
|
2021-04-16 |
2023-10-19 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
CA3217792A1
(en)
|
2021-05-07 |
2022-11-10 |
Kymera Therapeutics, Inc |
Cdk2 degraders and uses thereof
|
|
TW202313610A
(zh)
|
2021-06-09 |
2023-04-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之三環雜環
|
|
CA3220274A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
|
IL310924A
(en)
|
2021-08-25 |
2024-04-01 |
Pic Therapeutics Inc |
Eif4e inhibitors and uses thereof
|
|
US12157732B2
(en)
|
2021-08-25 |
2024-12-03 |
PIC Therapeutics, Inc. |
eIF4E inhibitors and uses thereof
|
|
JP2024540080A
(ja)
|
2021-10-29 |
2024-10-31 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ４分解剤およびその合成
|
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
CA3240810A1
(en)
*
|
2021-12-13 |
2023-06-22 |
Signet Therapeutics Inc. |
Pyrimidine or pyridine derivative and pharmaceutical use thereof
|
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
EP4472967A4
(en)
|
2022-01-31 |
2026-04-15 |
Kymera Therapeutics Inc |
Iraqi Degradation Agents and Their Uses
|
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
US12233056B2
(en)
|
2022-04-06 |
2025-02-25 |
Syntara Limited |
Lysyl oxidase inhibitors for treating myeloid malignancies
|
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
|
US20250302954A1
(en)
|
2022-05-11 |
2025-10-02 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
CN119768393A
(zh)
|
2022-05-25 |
2025-04-04 |
医肯纳肿瘤学公司 |
Mek抑制剂和其用途
|
|
US11786531B1
(en)
|
2022-06-08 |
2023-10-17 |
Beigene Switzerland Gmbh |
Methods of treating B-cell proliferative disorder
|
|
EP4565569A1
(en)
|
2022-08-02 |
2025-06-11 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
|
EP4565568A1
(en)
|
2022-08-02 |
2025-06-11 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
|
CN115448906B
(zh)
*
|
2022-09-26 |
2024-04-02 |
深圳大学 |
一种2-苯胺基嘧啶类衍生物及其制备方法与应用
|
|
WO2024112894A1
(en)
|
2022-11-22 |
2024-05-30 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
US20250059164A1
(en)
|
2023-06-23 |
2025-02-20 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
EP4780462A1
(en)
|
2023-09-21 |
2026-07-29 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
|
|
CN121752549A
(zh)
*
|
2023-09-22 |
2026-03-27 |
江苏恒瑞医药股份有限公司 |
杂芳基类化合物、其制备方法及其在医药上的应用
|
|
CN119707835A
(zh)
*
|
2024-11-25 |
2025-03-28 |
沈阳药科大学 |
2-氨基嘧啶-5-甲酰胺类化合物及用于制备治疗和/或预防癌症药物中的用途
|